Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod for moderately to severely active Crohn's disease
NL-OMON51883Phase 2Recruiting
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of etrasimod in Crohn's disease (3 arms), sponsored by Arena Pharmaceuticals, Inc. Primary endpoints: Endoscopic response at Week 14, Clinical remission by CDAI at Week 14 and 2 more. Started Jul 2021; status: recruiting.
02
Drugs
etrasimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON51883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51883.